Emergency reversal of anticoagulation: from theory to real use of prothrombin complex concentrates. A retrospective Italian experience. (avaa uuden ikkunan)

Barillari G, Pasca S, Barillari A, De Angelis V.

Lähde‎: Blood Transfus 2012;10(1):87-94.

Arkistoitu‎: PubMed 22044952

DOI‎: 10.2450/2011.0030-11

https://www.ncbi.nlm.nih.gov/pubmed/22044952 (avaa uuden ikkunan)

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (avaa uuden ikkunan)

Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R; American College of Chest Physicians.

Lähde‎: Chest 2012;141(2 Suppl):e326S-50S.

Arkistoitu‎: PubMed 22315266

DOI‎: 10.1378/chest.11-2298

https://www.ncbi.nlm.nih.gov/pubmed/22315266 (avaa uuden ikkunan)

Pharmacological prophylaxis of bleeding in surgical patients treated with aspirin. (avaa uuden ikkunan)

Flordal PA.

Lähde‎: Eur J Anaesthesiol Suppl 1997;14:38-41.

Arkistoitu‎: PubMed 9088834

https://www.ncbi.nlm.nih.gov/pubmed/9088834 (avaa uuden ikkunan)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (avaa uuden ikkunan)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Lähde‎: Lancet 2015;385(9982):2077-87.

Arkistoitu‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (avaa uuden ikkunan)

How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. (avaa uuden ikkunan)

Goodnough LT, Shander A.

Lähde‎: Blood 2011;117(23):6091-9.

Arkistoitu‎: PubMed 21411756

DOI‎: 10.1182/blood-2010-11-316075

https://www.ncbi.nlm.nih.gov/pubmed/21411756 (avaa uuden ikkunan)

Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. (avaa uuden ikkunan)

Hanke AA, Joch C, Görlinger K.

Lähde‎: Br J Anaesth 2013;110(5):764-72.

Arkistoitu‎: PubMed 23335567

DOI‎: 10.1093/bja/aes501

https://www.ncbi.nlm.nih.gov/pubmed/23335567 (avaa uuden ikkunan)

Reversing the effects of antiplatelet agents in the setting of intracranial hemorrhage: a look at the literature. (avaa uuden ikkunan)

Jaben EA, Mulay SB, Stubbs JR.

Lähde‎: J Intensive Care Med 2015;30(1):3-7.

Arkistoitu‎: PubMed 25492811

DOI‎: 10.1177/0885066613487298

https://www.ncbi.nlm.nih.gov/pubmed/25492811 (avaa uuden ikkunan)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (avaa uuden ikkunan)

Levi M, Eerenberg E, Kamphuisen PW.

Lähde‎: J Thromb Haemost 2011;9(9):1705-12.

Arkistoitu‎: PubMed 21729240

DOI‎: 10.1111/j.1538-7836.2011.04432.x

https://www.ncbi.nlm.nih.gov/pubmed/21729240 (avaa uuden ikkunan)

Emergency reversal of warfarin anticoagulation. (avaa uuden ikkunan)

Lin Y, Callum J.

Lähde‎: CMAJ 2010;182(18):2004.

Arkistoitu‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (avaa uuden ikkunan)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (avaa uuden ikkunan)

Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G.

Lähde‎: Thromb Haemost 2012;108(2):217-24.

Arkistoitu‎: PubMed 22627883

DOI‎: 10.1160/TH12-03-0179

https://www.ncbi.nlm.nih.gov/pubmed/22627883 (avaa uuden ikkunan)

Recent advances in the development of specific antidotes for target-specific oral anticoagulants. (avaa uuden ikkunan)

Mo Y, Yam FK.

Lähde‎: Pharmacotherapy 2015;35(2):198-207.

Arkistoitu‎: PubMed 25644580

DOI‎: 10.1002/phar.1532

https://www.ncbi.nlm.nih.gov/pubmed/25644580 (avaa uuden ikkunan)

Idarucizumab for dabigatran reversal - full cohort analysis. (avaa uuden ikkunan)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Lähde‎: N Engl J Med 2017;377(5):431-41.

Arkistoitu‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (avaa uuden ikkunan)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (avaa uuden ikkunan)

Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME.

Lähde‎: Anesth Analg 2011;113(4):703-10.

Arkistoitu‎: PubMed 21890888

DOI‎: 10.1213/ANE.0b013e318228c690

https://www.ncbi.nlm.nih.gov/pubmed/21890888 (avaa uuden ikkunan)

Oral anticoagulation in surgical procedures: risks and recommendations. (avaa uuden ikkunan)

Torn M, Rosendaal FR.

Lähde‎: Br J Haematol 2003;123(4):676-82.

Arkistoitu‎: PubMed 14616972

https://www.ncbi.nlm.nih.gov/pubmed/14616972 (avaa uuden ikkunan)

Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. (avaa uuden ikkunan)

Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW.

Lähde‎: Blood 2012;119(9):2172-4.

Arkistoitu‎: PubMed 22383791

DOI‎: 10.1182/blood-2011-11-393587

https://www.ncbi.nlm.nih.gov/pubmed/22383791 (avaa uuden ikkunan)